During the European Hematology Association (EHA) Annual Congress 2025, MPE conducted a series of expert interviews covering the most interesting updates in myeloma. These interviews focused on important research results and their potential to improve patient survival and quality of life.

• Dr. Sundar Jagannath discusses the long-term remission and survival for relapsed/refractory patients after treatment with ciltacabtagene autoleucel from the CARTITUDE-1 study, and considers a definition of cure in myeloma. Watch here.

• We spoke with Monique Minnema about the initial phase 1 results of JNJ-5322, a novel, next-generation trispecific antibody, in patients with relapsed/refractory myeloma. Watch here.

• Shaji Kumar presents the results of REDIRECTT-1, a phase 2 study of talquetamab and teclistamab in patients with relapsed/refractory myeloma and extramedullary disease. Watch here.

• MPE interviewed Martin Kaiser about the new classification system for high-risk myeloma, what this new classification means for patients and what the advocacy community can do to improve outcomes for high-risk myeloma patients. Watch here.

• Xavier Leleu shares results from the phase 3 IRAKLIA study of isatuximab subcutaneous via an on-body delivery system versus isatuximab intravenous, plus pomalidomide and dexamethasone, for relapsed/refractory patients. Watch here.

• Krzysztof Giannopoulos discusses the results of the PREDATOR-MRD randomised clinical trial looking at daratumumab or observation in myeloma patients who have not clinically relapsed after successful treatment but have a small number of myeloma cells reappear in the bone marrow, such as measurable residual disease (MRD) reappearance. Watch here.

• MPE interviewed Lisa Leypoldt about the results of transplant ineligible patients from the GMMG-CONCEPT trial looking at isatuximab, carfilzomib, lenalidomide, and dexamethasone (ISA-KRD) for high-risk newly diagnosed myeloma patients. Watch here.

• Francesco Sparano from Fondazione GIMEMA Franco Mandelli onlus explains the results from the GIMEMA-CLARITY study on the link between quality of life and socio-economic status of myeloma patients in Italy and the UK. Watch here.

• The MPE Head of Patient Research, Eilidh Duncan, presented the results of our Shared Decision-Making (SMD) research. In this video interview, Eilidh explains the key aspects, challenges and recommendations of this concept. Watch here.